Safety of intravenous tobramycin in combination with a variety of anti-pseudomonal antibiotics in children with cystic fibrosis

SAGE Open Medicine
Ashley R DeschampStephanie D Davis

Abstract

Previous studies have examined renal safety of once daily intravenous tobramycin in individuals with cystic fibrosis. This has been mainly in combination with ceftazidime in an adolescent or adult population. In this report, we describe our institutional experience of once daily intravenous tobramycin in combination with a variety of second anti-pseudomonal antibiotics in children with cystic fibrosis. We present a retrospective review including children with cystic fibrosis, who were admitted for a pulmonary exacerbation from January 2009 to December 2011, and treated using intravenous tobramycin. A literature review of once daily intravenous aminoglycoside dosing in cystic fibrosis was performed to compare our results to existing literature. A total of 35 subjects were divided into once daily dosing (n = 20) versus multiple daily dosing (n = 15) groups. Mean age was 11.3 years (± 5.7) for the once daily dosing group and 13.1 years (± 4.4) for the multiple daily dosing group (p = 0.34). All subjects had normal baseline serum creatinine at admission (once daily dosing 0.49 ± 0.14 mg/dL vs multiple daily dosing 0.62 ± 0.23 mg/dL, p = 0.07). All subjects received intravenous tobramycin, and most received piperacillin-tazobactam a...Continue Reading

References

Jul 1, 1997·Clinical Pediatrics·S J TeachL G Feld
Feb 28, 2002·The European Respiratory Journal·A WhiteheadS Bogle
Jul 3, 2004·Pediatrics·Despina G Contopoulos-IoannidisJohn P A Ioannidis
Mar 3, 2007·Critical Care : the Official Journal of the Critical Care Forum·Ravindra L MehtaUNKNOWN Acute Kidney Injury Network
Nov 28, 2008·Current Opinion in Biotechnology·Michael N DudleyDavid C Griffith
Jan 23, 2009·Journal of the American Society of Nephrology : JASN·George J SchwartzSusan L Furth
Mar 31, 2009·Pediatric Pulmonology·Daniel J Van MeterThomas Lahiri
Sep 5, 2009·American Journal of Respiratory and Critical Care Medicine·Patrick A FlumeUNKNOWN Clinical Practice Guidelines for Pulmonary Therapies Committee
Sep 4, 2010·Current Opinion in Pulmonary Medicine·Andrew Prayle, Alan R Smyth
Mar 2, 2013·Current Opinion in Pulmonary Medicine·Oana CiofuNiels Høiby

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.